We sought to investigate the safety and potentialbenefit of administrating glycoprotein IIb‐IIIa inhibitors (GPIs) on top of more potent P2Y12 inhibitors. Apr 11, 2024 · As such, clinicians should weigh the potentialbenefits against the risks of bleeding events before employing GPI in ACS patients. However, the beneficial effect of GPI on MACE should encourage their use in selected high-risk patients even if they are receiving potent P 2 Y 12 inhibitors. Considerable evidence has accumulated regarding the benefits from GP IIb–IIIa inhibitors on mortality, especially among high-riskpatients and when administered as an upstream strategy. Jul 30, 2024 · While GPIs can significantly reduce the risk of major adverse cardiovascular events, their use is accompanied by an increased risk of bleeding. Therefore, a personalized approach, weighing the benefits against the risks, is crucial in optimizing patient outcomes. Oct 26, 2022 · The GPI agents are sometimes given selectively to patients with STEMI and high thrombus burden or to lessen risk for severe thrombotic events, especially in patients requiring thrombus... Jan 13, 2023 · Development of GP IIb/IIIa inhibitors with oral administration has the potential to include short-term antiplatelet benefits compared with intravenous GP IIb/IIIa inhibitors for long-term secondary preventive therapy in cardiovascular disease.